Клинический разбор в общей медицине

Ревматоидный артрит ассоциирован с повышенным риском сердечной недостаточности, что обусловлено хроническим воспалением, играющим центральную роль в его патогенезе. У пациентов с ревматоидным артритом дисфункция миокарда может оставаться субклинической, в то время как сердечная недостаточность часто представлена в форме с сохраняющейся фракцией выброса. В статье рассматриваются основные механизмы возникновения сердечной недостаточности у пациентов с ревматоидным артритом, а также диагностические и терапевтические подходы. Существуют значительные проблемы с диагностикой сердечной недостаточности, особенно на фоне внедрения современных методов лечения, способных улучшить исходы заболевания и качество жизни. Раннее и целенаправленное лечение воспалительных процессов имеет первостепенное значение. Однако требуется дальнейшее исследование для понимания биологических механизмов, лежащих в основе этой взаимосвязи, а также для оценки стратегий лечения. Будущие исследования могут выявить биомаркеры, предсказывающие риск сердечной недостаточности, а также оценить эффективность противовоспалительных вмешательств в профилактике и лечении этой патологии у пациентов с ревматоидным артритом. 
Ключевые слова: ревматоидный артрит, сердечная недостаточность, хроническое воспаление, лечение, диагностика, лечение, сердечно-сосудистые заболевания, биомаркеры.

1. Насонов Е.Л., Авдеева А.С., Дибров Д.А. Ревматоидный артрит как клинико-иммунологический синдром: фокус на серонегативный субтип заболевания. Научно-практическая ревматология. 2023;61(3):276-91.
Nasonov E.L., Avdeeva A.S., Dibrov D.A. Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease. Rheumatology Science and Practice. 2023;61(3):276-91. DOI: 10.47360/1995-4484-2023-276-291 (in Russian).
2. Паневин Т.С., Роживанов Р.В., Зоткин Е.Г. и др. Клинико-лабораторные особенности ревматоидного артрита у мужчин в зависимости от уровня тестостерона. Проблемы Эндокринологии. 2024;70(3):98-104. DOI: 10.14341/probl13373
Panevin T.S., Rozhivanov R.V., Zotkin E.G. et al. Clinical and laboratory features of rheumatoid arthritis in men depending on testosterone levels. Problems of Endocrinology. 2024;70(3):98-104. DOI: 10.14341/probl13373 (in Russian).
3. Gravallese EM, Firestein GS. Rheumatoid Arthritis – Common Origins, Divergent Mechanisms. N Engl J Med 2023;388(6):529-42. DOI: 10.1056/NEJMra2103726.
4. Cutolo M, Straub RH. Sex steroids and autoimmune rheumatic diseases: state of the art. Nat Rev Rheumatol 2020;16(11):628-44. DOI: 10.1038/s41584-020-0503-4
5. Ребров А.П. Поражение сердца у больных с ревматоидным артритом. Южно-Российский журнал терапевтической практики. 2022;3(1):15-9. DOI: 10.21886/2712-8156-2022-3-1-15-19
Rebrov A.P. Heart damage in patients with rheumatoid arthritis. South Russian Journal of Therapeutic Practice 2022;3(1):15-9. DOI: 10.21886/2712-8156-2022-3-1-15-19 (in Russian).
6. Huang S, Cai T, Weber BN et al. Association Between Inflammation, Incident Heart Failure, and Heart Failure Subtypes in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2023;75(5):1036-45. DOI: 10.1002/acr.24804
7. Nikiphorou E, de Lusignan S, Mallen CD et al. Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study. Heart 2020;106(20):1566-72. DOI: 10.1136/heartjnl-2019-316193
8. Løgstrup BB. Heart Failure in Rheumatic Disease: Secular Trends and Novel Insights. Rheum Dis Clin North Am 2023;49(1):67-79. DOI: 10.1016/j.rdc.2022.08.003
9. Conrad N, McInnes IB, Mcmurray JJV, Sattar N. Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management? Ann Rheum Dis 2023;82(4):457-9. DOI: 10.1136/ard-2022-223315
10. Park E, Ito K, Iqbal R, Amigues I et al. Prospective changes in diastolic function in patients with rheumatoid arthritis. Arthritis Res Ther 2022;24(1):184. DOI: 10.1186/s13075-022-02864-0
11. Thallapally VK, Bansal R, Thandra A et al. Detection of myocardial dysfunction using global longitudinal strain with speckle-tracking echocardiography in patients with vs without rheumatoid arthritis: a systematic review and meta-analysis. J Echocardiogr 2023;21(1):23-32. DOI: 10.1007/s12574-022-00583-8
12. McDonagh TA, Metra M, Adamo M et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599-726. DOI: 10.1093/eurheartj/ehab368
13. Faxén J, Benson L, Mantel Ä et al. Associations between rheumatoid arthritis, incident heart failure, and left ventricular ejection fraction. Am Heart J 2023;259:42-51. DOI: 10.1016/j.ahj.2023.02.001
14. Ahlers MJ, Lowery BD, Farber-Eger E et al. Heart Failure Risk Associated With Rheumatoid Arthritis-Related Chronic Inflammation. J Am Heart Assoc 2020;9(10):e014661. DOI: 10.1161/JAHA.119.014661
15. Ferreira MB, Fonseca T, Costa R et al. Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. Eur J Intern Med 2021;85:41-9. DOI: 10.1016/j.ejim.2020.11.002
16. Norouzi S, Khalaji A, Namazi M et al. Ventricular and atrial function assessment with transthoracic echocardiography in patients with rheumatic inflammatory disease. Egypt Heart J 2022;74(1):81. DOI: 10.1186/s43044-022-00319-0
17. Баланова Ю.А., Концевая А.В., Шальнова С.А. и др. Распространенность поведенческих факторов риска сердечно-сосудистых заболеваний в российской популяции по результатам исследования ЭССЕ-РФ. Профилактическая медицина. 2014;17(5):42-52.
Balanova Yu.A., Kontseva A.V., Shalnova S.A. et al. Prevalence of behavioral risk factors for cardiovascular diseases in the Russian population according to the results of the ESSE-RF study. Russian Journal of Preventive Medicine. 2014;17(5):42-52. (in Russian).
18. Рациональное применение нестероидных противовоспалительных препаратов в клинической практике (клинические рекомендации). Часть 2. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(5):94-9.
Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Part II. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(5):94-9. DOI: 10.17116/jnevro20151155194-99 (in Russian).
19. Khalid Y, Dasu N, Shah A et al. Incidence of congestive heart failure in rheumatoid arthritis: a review of literature and meta-regression analysis. ESC Heart Fail 2020;7(6):3745-3753. DOI: 10.1002/ehf2.12947
20. Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. J Am Coll Cardiol 2023;81(18):1810-34. DOI: 10.1016/j.jacc.2023.01.049
21. Myasoedova E, Crowson CS, Nicola PJ et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011;38(8):1601-6. DOI: 10.3899/jrheum.100979
22. Mantel Ä, Holmqvist M, Andersson DC et al. Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure. J Am Coll Cardiol 2017;69(10):1275-85. DOI: 10.1016/j.jacc.2016.12.033
23. Sanders-van Wijk S, van Empel V, Davarzani N et al; TIME-CHF investigators. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail 2015;17(10):1006-14. DOI: 10.1002/ejhf.414
24. Park E, Griffin J, Bathon JM. Myocardial Dysfunction and Heart Failure in Rheumatoid Arthritis. Arthritis Rheumatol 2022;74(2):184-99. DOI: 10.1002/art.41979
25. Chen J, Norling LV, Cooper D. Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. Cells 2021;10(4):881. DOI: 10.3390/cells10040881
26. Combes A, Frye CS, Lemster BH et al. Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes. Pflugers Arch 2002 Nov;445(2):246-56. DOI: 10.1007/s00424-002-0921-y
27. Westermann D, Lindner D, Kasner M et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011;4(1):44-52. DOI: 10.1161/CIRCHEARTFAILURE.109.931451
28. Mavrogeni S, Karabela G, Stavropoulos E et al. Imaging patterns of heart failure in rheumatoid arthritis evaluated by cardiovascular magnetic resonance. Int J Cardiol 2013;168(4):4333-5. DOI: 10.1016/j.ijcard.2013.05.085
29. Кактурский Л.В., Михалева Л.М., Гиоева З.В., Гутырчик Н.А. Роль дисбаланса белков клеточной адгезии миокарда в нарушении сердечного ритма и декомпенсации сердечной деятельности. Архив патологии. 2024;86(5):75-80. DOI: 10.17116/patol20248605175
Kakturskiy L.V., Mikhaleva L.M., Gioeva Z.V., Gutyrchik N.A. The role of imbalance of myocardial cell adhesion proteins in cardiac arrhythmia and heart failure. Russian Journal of Archive of Pathology. 2024;86(5):75-80. DOI: 10.17116/patol20248605175 (in Russian).
30. Grundtman C, Hollan I, Førre OT et al. Cardiovascular disease in patients with inflammatory rheumatic disease is associated with up-regulation of markers of inflammation in cardiac microvessels and cardiomyocytes. Arthritis Rheum 2010;62(3):667-73. DOI: 10.1002/art.27264
31. Liao KP, Huang J, He Z, Cremone G et al. Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus and Association With All-Cause Mortality. Arthritis Care Res (Hoboken) 2021;73(2):159-65. DOI: 10.1002/acr.24108
32. Amigues I, Tugcu A, Russo C et al. Myocardial Inflammation, Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography, Is Associated With Disease Activity in Rheumatoid Arthritis. Arthritis Rheumatol 2019;71(4):496-506. DOI: 10.1002/art.40771
33. Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 5):v29-v34. DOI: 10.1093/rheumatology/kez346
34. Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA 2023;329(10):827-838. DOI: 10.1001/jama. 2023.2020
35. Avouac J, Meune C, Chenevier-Gobeaux C et al. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. J Rheumatol 2014;41(2):248-55. DOI: 10.3899/jrheum.130713
36. Shah SJ. BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction. Eur Heart J 2022;43(20):1952-4. DOI: 10.1093/eurheartj/ehac121
37. Verbrugge FH, Omote K, Reddy YNV et al. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur Heart J 2022;43(20):1941-51. DOI: 10.1093/eurheartj/ehab911
38. Mirjafari H, Welsh P, Verstappen SM et al. N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Ann Rheum Dis 2014;73(4):684-90. DOI: 10.1136/annrheumdis-2012-202848
39. Targońska-Stępniak B, Biskup M, Biskup W, Majdan M. Diastolic dysfunction in rheumatoid arthritis patients with low disease activity. Clin Rheumatol 2019;38(4):1131-7. DOI: 10.1007/s10067-018-4369-7
40. Васюк Ю.А., Шупенина Е.Ю., Намазова Г.А., Дубровская Т.И. Новые алгоритмы диагностики сердечной недостаточности с сохраненной фракцией выброса левого желудочка у пациентов с артериальной гипертензией и ожирением. Кардиоваскулярная терапия и профилактика. 2021;20(1):2569. DOI: 10.15829/1728-8800-2021-2569
Vasyuk Yu.A., Shupenina E.Yu., Namazova G.A., Dubrovskaya T.I. Novel algorithms for diagnosing heart failure with preserved ejection fraction in patients with hypertension and obesity. Cardiovascular Therapy and Prevention. 2021;20(1):2569. DOI: 10.15829/1728-8800-2021-2569 (in Russian).
41. Pieske B, Tschöpe C, de Boer RA et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40(40):3297-317. DOI: 10.1093/eurheartj/ehz641
42. Plein S, Erhayiem B, Fent G et al. Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis. Ann Rheum Dis 2020;79(11):1414-22. DOI: 10.1136/annrheumdis-2020-217653
43. Cioffi G, Viapiana O, Ognibeni F et al. Prognostic Role of Subclinical Left Ventricular Systolic Dysfunction Evaluated by Speckle-Tracking Echocardiography in Rheumatoid Arthritis. J Am Soc Echocardiogr 2017;30(6):602-11. DOI: 10.1016/j.echo.2017.02.001
44. Ji X, Zhang X, Li G. A preliminary study on the evaluation of left atrial function of rheumatoid arthritis by two dimensional speckle tracking imaging. Sci Rep 2021;11(1):21537. DOI: 10.1038/s41598-021-00657-0
45. Azpiri-Lopez JR, Galarza-Delgado DA, Colunga-Pedraza IJ et al. Echocardiographic evaluation of pulmonary hypertension, right ventricular function, and right ventricular-pulmonary arterial coupling in patients with rheumatoid arthritis. Clin Rheumatol 2021;40(7):2651-6. DOI: 10.1007/s10067-020-05544-z
46. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099. DOI: 10.1136/bmj.j2099
47. Salaffi F, Carotti M, Di Carlo M et al. The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthrit. Swiss Med Wkly 2018;148:w14656. DOI: 10.4414/smw.2018.14656
48. Heidenreich PA, Bozkurt B, Aguilar D et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1. Erratum in: Circulation. 2022 May 3;145(18):e1033. DOI: 10.1161/CIR.0000000000001073
49. Packer M. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis. Circulation 2022;146(18):1383-405. DOI: 10.1161/CIRCULATIONAHA.122.061732
50. Fraenkel L, Bathon JM, England BR et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumato 2021;73(7):1108-23. DOI: 10.1002/art.41752
51. Thornton CC, Al-Rashed F, Calay D et al. Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis 2016;75(2):439-48. DOI: 10.1136/annrheumdis-2014-206305
52. Ronda N, Greco D, Adorni MP et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol 2015;67(5):1155-64. DOI: 10.1002/art.39039
53. Shervington L, Darekar A, Shaikh M et al. Identifying Reliable Diagnostic/Predictive Biomarkers for Rheumatoid Arthritis. Biomark Insights 2018;13:1177271918801005. DOI: 10.1177/1177271918801005
54. Lang MB, Leung KY, Greene NDE et al. The actions of methotrexate on endothelial cells are dependent on the shear stress-induced regulation of one carbon metabolism. Front Immunol 2023;14:1209490. DOI: 10.3389/fimmu.2023.1209490
55. Young SP, Kapoor SR, Viant MR et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum 2013;65(8):2015-23. DOI: 10.1002/art.38021
56. Ridker PM, Everett BM, Pradhan A et al; CIRT Investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med 2019;380(8):752-62. DOI: 10.1056/NEJMoa1809798
57. Solomon DH, Glynn RJ, Rothman KJ et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008;59(8):1097-104. DOI: 10.1002/art.23911
58. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006;55(4):531-6. DOI: 10.1002/art.22094
59. Solomon DH, Avorn J, Katz JN et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(12):3790-8. DOI: 10.1002/art.22255
60. Kim HW, Han M, Jung I, Ahn SS. New-onset atrial fibrillation in seropositive rheumatoid arthritis: association with disease-modifying anti-rheumatic drugs treatment. Rheumatology (Oxford) 2024;63(3):630-8. DOI: 10.1093/rheumatology/kead336
61. Naranjo A, Sokka T, Descalzo MA et al; QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10(2):R30. DOI: 10.1186/ar2383
62. Boers M, Nurmohamed MT, Doelman CJ et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62(9):842-5. DOI: 10.1136/ard.62.9.842
63. Chatre C, Roubille F, Vernhet H et al. Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Drug Saf 2018;41(10):919-31. DOI: 10.1007/s40264-018-0689-4
64. Malhotra A, Pathak MA, Dalia T, Vidic A. Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis. BMJ Case Rep 2023;16(4):e252327. DOI: 10.1136/bcr-2022-252327
65. D'Andrea E, Desai RJ, He M et al. Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis. J Am Coll Cardiol 2022;80(1):36-46. DOI: 10.1016/j.jacc.2022.04.039
66. Roubille C, Richer V, Starnino T et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74(3):480-9. DOI: 10.1136/annrheumdis-2014-206624
67. Setoguchi S, Schneeweiss S, Avorn J et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008;156(2):336-41. DOI: 10.1016/j.ahj.2008. 02.025
68. Baniaamam M, Handoko ML, Agca R et al. The Effect of Anti-TNF Therapy on Cardiac Function in Rheumatoid Arthritis: An Observational Study. J Clin Med 2020;9(10):3145. DOI: 10.3390/jcm9103145
69. Bozkurt B, Torre-Amione G, Warren MS et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103(8):1044-7. DOI: 10.1161/01.cir.103.8.1044
70. Coletta AP, Clark AL, Banarjee P, Cleland JG. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002;4(4):559-61. DOI: 10.1016/s1388-9842(02)00121-6
71. Mann DL, McMurray JJ, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109(13):1594-602. DOI: 10.1161/01.CIR.0000124490.27666.B2
72. Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 2007;27(4):369-73. DOI: 10.1007/s00296-006-0215-3
73. Chung ES, Packer M, Lo KH et al; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107(25):3133-40. DOI: 10.1161/01.CIR.0000077913.60364.D2
74. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116(5):305-11. DOI: 10.1016/j.amjmed.2003.09.039
75. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005;44(5):677-80. DOI: 10.1093/rheumatology/keh610
76. Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 2012;18(11):1543-55. DOI: 10.2174/138161212 799504759
77. Халиков А.А., Кузнецов К.О., Искужина Л.Р., Халикова Л.В. Судебно-медицинские аспекты внезапной аутопсия-отрицательной сердечной смерти. Судебно-медицинская экспертиза. 2021;64(3):59-63. DOI: 10.17116/sudmed20216403159
Khalikov A.A., Kuznetsov K.O., Iskuzhina L.R., Khalikova L.V. Forensic aspects of sudden autopsy-negative cardiac death. Forensic Medical Expertise 2021;64(3):59-63. DOI: 10.17116/sudmed20216403159 (in Russian).
78. Zhang J, Xie F, Yun H et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016;75(10):1813-8. DOI: 10.1136/annrheumdis-2015-207870
79. Ikonomidis I, Tzortzis S, Andreadou I et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging 2014;7(4):619-28. DOI: 10.1161/CIRCIMAGING.113.001193
80. Ridker PM, Everett BM, Thuren T et al; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017;377(12):1119-31. DOI: 10.1056/NEJMoa1707914
81. Everett BM, Cornel JH, Lainscak M et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation 2019;139(10):1289-99. DOI: 10.1161/CIRCULATIONAHA
82. Charles-Schoeman C, Wicker P, Gonzalez-Gay MA et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum 2016;46(3):261-71. DOI: 10.1016/j.semarthrit.2016.05.014
83. Charles-Schoeman C, DeMasi R, Valdez H et al. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis Rheumatol 2019;71(9):1450-9. DOI: 10.1002/art.40911
84. Charles-Schoeman C, Buch MH, Dougados M et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis 2023;82(1):119-29. DOI: 10.1136/ard-2022-222259
85. Xie W, Huang Y, Xiao S et al. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 2019;78(8):1048-54. DOI: 10.1136/annrheumdis-2018-214846
86. del Rincón I, Polak JF, O'Leary DH et al. Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis 2015;74(6):1118-23. DOI: 10.1136/annrheumdis-2013-205058
87. Coxib and traditional NSAID Trialists' (CNT) Collaboration; Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382(9894):769-79. DOI: 10.1016/S0140-6736(13)60900-9
88. Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol 2016;82(4):957-64. DOI: 10.1111/bcp.13048
89. Nissen SE, Yeomans ND, Solomon DH et al; PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med 2016;375(26):2519-29. DOI: 10.1056/NEJMoa1611593
90. Fosbøl EL, Folke F, Jacobsen S et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010;3(4):395-405. DOI: 10.1161/CIRCOUTCOMES.109.861104

Портал CON-MED.RU:
https://con-med.ru/magazines/klinicheskiy_razbor_v_obshchey_meditsine/klinicheskiy_razbor_v_obshchey_meditsine-03-2025/vliyanie_revmatoidnogo_artrita_na_risk_serdechnoy_nedostatochnosti_mekhanizmy_diagnostika_i_podkhody/